HUMAN GENETIC STUDY
CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction
Article first published online: 25 JUL 2011
© 2011 The Authors, Addiction Biology © 2011 Society for the Study of Addiction
Volume 18, Issue 4, pages 709–716, July 2013
How to Cite
Levran, O., Peles, E., Hamon, S., Randesi, M., Adelson, M. and Kreek, M. J. (2013), CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addiction Biology, 18: 709–716. doi: 10.1111/j.1369-1600.2011.00349.x
- Issue published online: 23 JUN 2013
- Article first published online: 25 JUL 2011
Figure S1 Correlation between trough methadone plasma levels and daily methadone doses.
Figure S2 Structure analysis of the sample anchored to 1051 subjects (HGDP-CEPH) as reference, using 4 clusters correspond to Africa, Europe, Middle East and Asia.
Figure S3 Pair-wise LD analysis between SNPs in CYP2B6 and CYP2D6.
Table Sl Primers sequences.
Table S2 Sample data.
Table S3 Biographical Ancestry Scores based on Structure analysis of AIMs data.
Table S4 SNPs not variable in the study sample.
Table S5 Individual SNP association analysis with methadone daily doses.
|adb349_sm_fs1.pdf||8K||Supporting info item|
|adb349_sm_fs2.pdf||120K||Supporting info item|
|adb349_sm_fs3a.pdf||20K||Supporting info item|
|adb349_sm_fs3b.pdf||17K||Supporting info item|
|adb349_sm_fs3c.pdf||16K||Supporting info item|
|adb349_sm_fs3d.pdf||13K||Supporting info item|
|adb349_sm_suppinfor.doc||366K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.